Known targets — ChEMBL curated mechanism
FAURPL10RPL10ARPL11RPL12RPL13RPL13ARPL14RPL15RPL17RPL18RPL18ARPL19RPL21RPL22RPL23RPL23ARPL24RPL26RPL27RPL27ARPL28RPL29RPL3RPL30RPL31RPL32RPL34RPL35RPL35ARPL36RPL36ARPL37RPL37ARPL38RPL39RPL4RPL41RPL5RPL6RPL7RPL7ARPL8RPL9RPL9P7RPL9P8RPL9P9RPLP0RPLP1RPS10RPS11RPS12RPS13RPS14RPS15RPS15ARPS16RPS17RPS18RPS19RPS2RPS20RPS21RPS23RPS24RPS25RPS26RPS27RPS27ARPS28RPS29RPS3RPS3ARPS4XRPS4Y1RPS5RPS6RPS7RPS8RPS9RPSA
The experimentally established mechanism targets of Ataluren. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | BLVRB | P30043 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 13/20 | 0.79 |
| ▸ | RAB9A | P51151 | 13/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.69 |
| ▸ | RELA | Q04206 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ataluren SCHEMBL29360108 | 1.00 | MAOA (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| Ataluren SCHEMBL29365205 | 1.00 | MAOA (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| Ataluren SCHEMBL29361641 | 1.00 | MAOA (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| Ataluren SCHEMBL59167 | 0.99 | MAOA (0.97) | MAOABLVRBHDAC6NPC1RAB9A | |
| Ataluren SCHEMBL59165 | 0.99 | MAOA (0.97) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL60044 | 0.91 | MAOA (0.83) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL1505230 | 0.90 | MAOA (0.81) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL60083 | 0.89 | HDAC6 (0.80) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL1752479 | 0.88 | NPC1 (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL17946207 | 0.88 | MAOA (0.79) | MAOABLVRBHDAC6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-17 | — | — | US | claimed |
| WO-2025110781-A1 | BIOMARKER COMPOSITION COMPRISING AMPD3 FOR PREDICTING SENSITIVITY TO THERAPEUTIC AGENT FOR NEUROFIBROMATOSIS, AND PHARMACEUTICAL COMPOSITION COMPRISING AMPD3 INHIBITOR FOR PREVENTING OR TREATING NEUROFIBROMATOSIS | 재단법인 아산사회복지재단 | 2025-05-30 | — | — | WO | claimed |
| US-20250137059-A1 | ACTIVATED RAS AS THERAPEUTIC AND DIAGNOSTIC TARGET FOR NEUROFIBROMATOSIS AND USE THEREOF | THE ASAN FOUNDATION (KR) | 2025-05-01 | — | — | US | claimed |
| EP-4473971-A2 | METHOD FOR TREATING NONSENSE MUTATION MEDIATED DUCHENNE MUSCULAR DYSTROPHY IN PEDIATRIC PATIENTS | PTC Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4455670-A1 | ACTIVATED RAS AS THERAPEUTIC AND DIAGNOSTIC TARGET FOR NEUROFIBROMATOSIS AND USE THEREOF | The Asan Foundation (KR) | 2024-10-30 | — | — | EP | claimed |
| US-20240352461-A1 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-24 | — | — | US | claimed |
| CN-114920667-B | Electrochemical preparation method of atta Lu Lunzhi | 湖南大学 | 2024-06-21 | — | — | CN | claimed |
| EP-3591052-B1 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2023-08-30 | — | — | EP | claimed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | claimed |
| US-20230218587-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-13 | — | — | US | claimed |
| WO-2008039431-A2 | CRYSTALLINE FORMS OF 3-[5-(2-FHJOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID | PTC THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| EP-1874306-A1 | COMPOSITIONS OF AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC Therapeutics, Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| US-20070161687-A1 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | PTC THERAPEUTICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7202262-B2 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| WO-2006110483-A1 | COMPOSITIONS OF AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. (US) | 2006-10-19 | — | — | WO | claimed |
| CN-1802360-A | 1,2, 4-oxadiazole benzoic acid compounds | PTC THERAPEUTICS INC (US) | 2006-07-12 | — | — | CN | claimed |
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | claimed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | PCT THERAPEUTICS, INC. | 2005-07-28 | — | — | US | claimed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218587-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | SMN1; SMN2, UPF1, VHL | MAOA 2571/4885BLVRB 2211/4885HDAC6 396/4885 |
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | MAOA 3474/4885BLVRB 2415/4885HDAC6 620/4885 |
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | APP, APBA1, PRNP | MAOA 1118/4885BLVRB 1212/4885HDAC6 2055/4885 |
| US-20070161687-A1 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | UPF1, PABPC4, PABPC1 | MAOA 3625/4885BLVRB 2775/4885HDAC6 2378/4885 |
| US-20250137059-A1 | ACTIVATED RAS AS THERAPEUTIC AND DIAGNOSTIC TARGET FOR NEUROFIBROMATOSIS AND USE THEREOF | NRAS, KRAS, RASGRP1 | MAOA 3897/4885BLVRB 2199/4885HDAC6 4788/4885 |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | UPF1, PABPC1, PABPC4 | MAOA 2579/4885BLVRB 2649/4885HDAC6 659/4885 |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | UPF1, PABPC1, PABPC4 | MAOA 3758/4885BLVRB 3084/4885HDAC6 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.